American Century Companies Inc. Buys 1,952 Shares of United Therapeutics Corporation $UTHR

American Century Companies Inc. lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 5.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,129 shares of the biotechnology company’s stock after purchasing an additional 1,952 shares during the period. American Century Companies Inc. owned approximately 0.08% of United Therapeutics worth $15,146,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. AQR Capital Management LLC increased its stake in shares of United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after buying an additional 364,713 shares during the period. Invesco Ltd. increased its position in United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the period. Norges Bank acquired a new stake in United Therapeutics in the second quarter worth about $136,453,000. Amundi raised its holdings in United Therapeutics by 3.6% during the 2nd quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock worth $107,113,000 after purchasing an additional 12,633 shares during the last quarter. Finally, First Trust Advisors LP raised its holdings in United Therapeutics by 2.5% during the 2nd quarter. First Trust Advisors LP now owns 305,512 shares of the biotechnology company’s stock worth $87,789,000 after purchasing an additional 7,484 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $535.81 on Wednesday. The company has a 50 day moving average price of $483.83 and a two-hundred day moving average price of $457.40. The company has a market capitalization of $23.48 billion, a PE ratio of 19.20, a PEG ratio of 1.91 and a beta of 0.84. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $548.12.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same period last year, the firm posted $6.19 earnings per share. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on UTHR shares. Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a report on Thursday, February 26th. Finally, UBS Group upped their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $539.00.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,000 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $489.42, for a total value of $978,840.00. Following the completion of the sale, the director directly owned 8,480 shares in the company, valued at $4,150,281.60. This represents a 19.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $518.03, for a total value of $4,921,285.00. Following the sale, the chief executive officer directly owned 130 shares in the company, valued at approximately $67,343.90. This represents a 98.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 344,497 shares of company stock worth $167,709,262 in the last three months. 10.30% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.